Culmination Bio, BillionToOne Partner to Validate Cancer Diagnostics
Culmination Bio, a data and technology company combining clinical and biospecimen data, announced a partnership with BillionToOne, Inc., a next-generation molecular diagnostics company
Source: hitconsultant.net